Fully human mAbs for septicaemia (AIMM Therapeutics/Genetech)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameFully human mAbs for septicaemia (AIMM Therapeutics/Genetech)
Drug Alias NameFully human mAbs for septicaemia (AIMM Therapeutics)anti staph mAb rF1 (AIMM Therapeutics/Genetech)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsStaphylococcal Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAimm Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAimm TherapeuticsGenentech Inc
Active IndicationsN/A
Inactive IndicationsStaphylococcal Infections

Other Information

ATC CodeN/A
Related LinksN/A